GE HealthCare aims to provide neuroscientists and researchers with a clearer view into the human mind, by using a specialized, “premium” MRI machine to help explore the brain’s structure and functi | ...

Walking Fish Therapeutics has closed after a lead investor backed out of a critical series B round. CEO Rusty Williams, M.D., Ph.D., said in an interview with Fierce Biotech that the biotech was on ...

Masimo secured FDA clearance for its Stork baby monitoring system that can help track certain vital signs in healthy infants up to 18 months old and provide alarms to parents or caregivers. The newly ...

Zenas BioPharma has bagged a $200 million series C, extending its cash runway another 18 months through a raft of key readouts for its lead monoclonal antibody obexelimab. | Zenas BioPharma has raised ...

Lykos Therapeutics’ MDMA-assisted therapy is charting yet another first in the psychedelic field: an FDA advisory meeting. The biotech will meet with the Psychopharmacologic Drugs Advisory Committee ...

Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab on June 10. | Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to ...

Now, Vertex is asking for the FDA to approve vanza triple for people with CF aged 6 years and older. The Boston-based company also completed a submission in Europe for the same indication and is on ...

Don’t call it a comeback — technically it’s a whole new regulatory clearance. | Outset Medical has resumed distributing its portable dialysis machine after halting sales last summer, now that it’s ...

A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.

Big Pharma veteran Jo Goodman is joining Celerion as vice president of bioanalytical services at the contract research organization’s Lincoln, Nebraska, lab. | Big Pharma veteran Jo Goodman is joining ...

Calliditas Therapeutics had a typical to-do list for its midphase head and neck cancer study. Step one, show the molecule shrinks tumors. | Calliditas Therapeutics had a typical to-do list for its ...

GlycoMimetics CEO Harout Semerjian told investors in March that phase 3 blood cancer results could “fundamentally impact our ...